Gilles Pernod
A5032514115- Venous Thromboembolism Diagnosis and Management
- Atrial Fibrillation Management and Outcomes
- Blood Coagulation and Thrombosis Mechanisms
- Acute Ischemic Stroke Management
- Diagnosis and Treatment of Venous Diseases
- Peripheral Artery Disease Management
- Healthcare Systems and Practices
- Central Venous Catheters and Hemodialysis
- Antiplatelet Therapy and Cardiovascular Diseases
- Acute Myocardial Infarction Research
- Platelet Disorders and Treatments
- Cardiac, Anesthesia and Surgical Outcomes
- Heparin-Induced Thrombocytopenia and Thrombosis
- Vitamin K Research Studies
- Vascular Procedures and Complications
- Angiogenesis and VEGF in Cancer
- Health Systems, Economic Evaluations, Quality of Life
- Protease and Inhibitor Mechanisms
- Hemophilia Treatment and Research
- Myeloproliferative Neoplasms: Diagnosis and Treatment
- Cardiac Arrhythmias and Treatments
- Health, Medicine and Society
- COVID-19 Clinical Research Studies
- Cell Adhesion Molecules Research
- Trauma, Hemostasis, Coagulopathy, Resuscitation
Université Grenoble Alpes
2016-2025
Translational Innovation in Medicine and Complexity
2016-2025
Centre National de la Recherche Scientifique
2016-2025
French Clinical Research Infrastructure Network
2018-2024
Centre Hospitalier Universitaire de Grenoble
2015-2024
Centre Hospitalier Universitaire de Saint-Étienne
2022-2024
Institut polytechnique de Grenoble
2024
VetAgro Sup
2024
Institut Gustave Roussy
2024
Société Française de Médecine Vasculaire
2008-2022
Summary The new anticoagulants dabigatran and rivaroxaban can be responsible for haemorrhagic complications. As any anticoagulant, bleeding management is challenging. We aimed to test the effect of all putative haemostatic agents on anticoagulant activity these drugs using thrombin generation tests. In an ex vivo study, 10 healthy white male subjects were randomised receive (20 mg) or (150 in one oral administration. After a two weeks washout period, they received other anticoagulant. Venous...
<h3>Importance</h3> The optimal duration of anticoagulation after a first episode unprovoked pulmonary embolism is uncertain. <h3>Objectives</h3> To determine the benefits and harms an additional 18-month treatment with warfarin vs placebo, initial 6-month nonrandomized period on vitamin K antagonist. <h3>Design, Setting, Participants</h3> Randomized, double-blind trial (treatment period, 18 months; median follow-up, 24 months); 371 adult patients who had experienced symptomatic (ie, no...
<b>Objective</b> To prospectively validate the HERDOO2 rule (Hyperpigmentation, Edema, or Redness in either leg; D-dimer level ≥250 μg/L; Obesity with body mass index ≥30; Older age, ≥65 years), which states that women none one of criteria can safely discontinue anticoagulants after short term treatment. <b>Design</b> Prospective cohort management study. <b>Setting</b> 44 secondary tertiary care centres seven countries. <b>Participants</b> Of 3155 consecutive eligible...
The aim of this study is to compare the Hestia rule vs. simplified Pulmonary Embolism Severity Index (sPESI) for triaging patients with acute pulmonary embolism (PE) home treatment.Normotensive PE 26 hospitals from France, Belgium, Netherlands, and Switzerland were randomized either or sPESI. They designated treatment if tool was negative physician-in-charge, taking into account patient's opinion, did not consider that hospitalization required. main outcomes 30-day composite recurrent venous...
In patients with venous thromboembolism at high risk of recurrence for whom extended treatment direct oral anticoagulants has been indicated, the optimal dose is unknown. We aimed to assess efficacy and safety reduced-dose versus full-dose in anticoagulation indicated. RENOVE was a non-inferiority, investigator-initiated, multicentre, randomised, open-label, blinded endpoint trial done 47 hospitals France. Ambulatory aged 18 years or older acute symptomatic (pulmonary embolism proximal deep...